Melanoma Detection
Conditions
Brief summary
This is a multi-center, sample collection study to follow clinically suspicious lesions to determine the outcome including surgical biopsy, removal, monitoring, etc. for up to 2 years after lesion identification. Subjects who had, or will have a DermTech Pigmented Lesion Assay completed on a lesion suspected of being melanoma are eligible for the study. Based on historical data, an expected melanoma rate of approximately 5% to 10% is anticipated.
Detailed description
This is a multi-center, sample collection study to follow clinically suspicious lesions to determine the outcome including surgical biopsy, removal, monitoring, etc. for up to 2 years after lesion identification. Subjects will be consented and enter the trial to have their suspicious lesion(s), biopsied via DermTech's adhesive patch biopsy and assessed with DermTech's non-invasive PLA, and followed up to 2 years per standard of care. Lesions must be photographed and/or the site of the lesion anatomically defined to permit follow-up of the lesion(s) and lesional site(s) during future visits. Subjects will be followed per standard of care for lesion biopsy, excision, treatment and/or monitoring. Other than DermTech's non-invasive PLA of the lesion(s) no other study procedures will be performed and subjects will be treated according to the standard of care. The subject's medical management team should use standard of care, visual assessment changes (i.e., ABCDE) and physician judgment for suspicious lesion characterization and monitoring when planning the subject's course of treatment.
Interventions
OTHERRepeat Testing
Repeat Testing with the PLA will be conducted
Sponsors
DermTech
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males and females the treating physician chose to use the PLA on; 2. Presence of a lesion(s) that is suspicious for melanoma and a candidate for surgical biopsy that was previously biopsied with DermTech's adhesive patch biopsy and assessed via PLA; 3. Willing to permit subsequent PLA assays to be performed on suspicious lesions; 4. Willing to follow standard of care treatment for the lesion(s) as determined by the treating physician; 5. Subjects must be able to complete study visits required by the protocol (subject is not planning to relocate or travel thus prevent attendance at future study visits; and 6. Willing to provide informed consent to participate in this trial.
Exclusion criteria
1. Has confirmed melanoma or a suspicious lesion that required a surgical biopsy or excision prior to the intial PLA on that lesion of interest; 2. Has an ulcerated or bleeding lesion that could cofound the PLA results; 3. Has a suspicious lesion(s) in an area that was previously surgically biopsied; 4. The lesion(s) is on the palms, mucosal surface, or other area where adhesive patch biopsies cannot be performed; 5. Has an allergy to tape or latex rubber; 6. Receipt of any investigational drug therapy within four weeks of study enrollment, or concurrent participation in another interventional clinical study deemed by the treating physician to potentially influence this study; and 7. Documented substance abuse, any other significant medical condition or laboratory result that would indicate an unreasonable risk to the subject or potential interference with study procedures, or would negatively affect the patient's reliability and compliance with the study schedule of events. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects without surgical biopsy | approximately up to 24 months | The proportion of subjects who exit the study without surgical biopsy out to approximately up to 24 months ± SOC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Results of PLA results compared to biopsy | approximately up to 24 months | Expression of genes during the 2-year study. The association of gene expression and algorithm values with melanoma versus non-melanoma will be examined using clinical performance indicators negative predictive value with their respective 95th percentile confidence intervals. |
Countries
United States
Outcome results
None listed